Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.35 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2673864 | 0.97 | NPSR1 (0.38) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL15829772 | 0.95 | SOAT1 (0.35) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL6420354 | 0.91 | NPSR1 (0.43) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL177754 | 0.87 | NPSR1 (0.47) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| Fumaric Acid SCHEMBL11046736 | 0.87 | ALDH1A1 (0.50) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL3319762 | 0.86 | CYP1A2 (0.44) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL6668912 | 0.85 | PAOX (0.48) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL4312640 | 0.83 | PAOX (0.52) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL30773553 | 0.83 | PAOX (0.52) | NPSR1PAOXCYP2C19MEN1KMT2A | |
| SCHEMBL29564926 | 0.83 | PAOX (0.52) | NPSR1PAOXCYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 473 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2025-03-06 | — | — | US | claimed |
| WO-2024069235-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2024-04-04 | — | — | WO | claimed |
| CN-116789553-A | Synthesis method of N, N-diethyl ethylenediamine | 甘肃省化工研究院有限责任公司 | 2023-09-22 | — | — | CN | claimed |
| EP-4245750-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | YIWUHUAYAO PHARMACEUTICAL TECHNOLOGY CO., LTD (CN) | 2023-09-20 | — | — | EP | claimed |
| US-20230183746-A1 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2023-06-15 | — | — | US | claimed |
| CN-115997016-A | Composition comprising nucleic acid nanoparticles having modular functional groups | 西克斯福德生物科学有限公司 | 2023-04-21 | — | — | CN | claimed |
| EP-4143316-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2023-03-08 | — | — | EP | claimed |
| CN-112225673-B | Amino combretastatin derivative and application thereof | 义乌市华耀医药科技有限公司 | 2022-08-02 | — | — | CN | claimed |
| EP-4022058-A2 | COMPOSITIONS FOR TRANSFER OF CARGO TO CELLS | Sixfold Bioscience Ltd. (GB) | 2022-07-06 | — | — | EP | claimed |
| WO-2021220053-A2 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | Sixfold Bioscience Ltd. (GB) | 2021-11-04 | — | — | WO | claimed |
| EP-1039297-A1 | Reagent for the determination of leucocytes and the measurement of hemoglobin in a blood sample | ABX (FR) | 2000-09-27 | — | — | EP | claimed |
| US-6114130-A | COMPRISING ONE DETERGENT OF THE CATIONIC TYPE, A COMPOUND OF THE GLYCOSIDE TYPE, AND IN PARTICULAR A SAPONIN, AT LEAST ONE INORGANIC SALT AND/OR AN OSMOTIC AND/OR LEUKOPROTECTIVE AGENT, AND AN ORGANIC AND/OR INORGANIC BUFFER | ABX (FR) | 2000-09-05 | — | — | US | claimed |
| US-6090252-A | NO ARTIFICIAL EXTRA BANDS DURING ELECTROPHORETIC SEPARATION BUT SHARP AND WELL-DEFINED BANDS OF MACROMOLECULES, E.G. PROTEINS, RESULT; GEL BUFFER SOLUTION CONTAINS A BASE AND TITRATING ACID, CATHODE ONE A WEAK ACID; STORAGE STABILITY | PHARMACIA BIOTECH AB (SE) | 2000-07-18 | — | — | US | claimed |
| EP-0978724-A1 | Reagent for the assay of hemoglobin and the determination of leukocytes in a blood sample | ABX (FR) | 2000-02-09 | — | — | EP | claimed |
| EP-0794827-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | Pharmacia Biotech AB (SE) | 1997-09-17 | — | — | EP | claimed |
| WO-1996039393-A1 | METHOD FOR PREPARING N, N'-DISUBSTITUED CYCLIC UREAS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-12-12 | — | — | WO | claimed |
| WO-1996016724-A1 | NEW BUFFER SYSTEM FOR ELECTROPHORESIS AND USE THEREOF | PHARMACIA BIOTECH AB (SE) | 1996-06-06 | — | — | WO | claimed |
| EP-0691961-A1 | SUBSTITUTED CAPROLACTAMS AND DERIVATIVES THEREOF USEFUL FOR TREATMENT OF HIV DISEASE | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-01-17 | — | — | EP | claimed |
| EP-0686151-A1 | SUBSTITUTED CYCLIC CARBONYLS AND DERIVATIVES THEREOF USEFUL AS RETROVIRAL PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-12-13 | — | — | EP | claimed |
| US-4122265-A | APPETITE SUPPRESSANTS | HOFFMANN-LA ROCHE INC. (US) | 1978-10-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074869-A1 | AMINO-COMBRETASTATIN DERIVATIVE AND USE THEREOF | TUBB3, TUBB6, TUBA3C | NPSR1 2748/4885PAOX 3356/4885CYP2C19 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.